Charles River Laboratories International
 
 
 
 
公司概覽
業務類別 Diagnostics & Research
業務概覽 Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
公司地址 251 Ballardvale Street, Wilmington, MA, USA, 01887
電話號碼 +1 781 222-6000
傳真號碼 --
公司網頁 https://www.criver.com
員工數量 19700
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Mr. Mark Mintz Corporate Executive Vice President and Chief Information Officer & Global Shared Services -- 18/02/2026
Ms. Birgit Girshick Chief Operating Officer and Director 美元 760.96K 09/01/2026
Mr. Joseph W. LaPlume Corporate Executive Vice President, Corporate Development and Strategy 美元 570.17K 18/02/2026
Ms. Shannon M. Parisotto Corporate Executive Vice President -- 18/02/2026
Mr. James C. Foster Chairman of the Board, President and Chief Executive Officer 美元 1.55M 09/01/2026
Mr. Michael Gunnar Knell Corporate Senior Vice President and Chief Accounting Officer 美元 448.12K 18/02/2026
Ms. Victoria L. Creamer Corporate Executive Vice President 美元 553.75K 18/02/2026
Mr. Glenn G. Coleman, C.P.A. Corporate Executive Vice President and Chief Financial Officer -- 18/02/2026
 
董事會成員
董事會 職務 更新日期
Mr. Steven K. Barg Independent Director 31/03/2026
Mr. Mark Joseph Enyedy Independent Director 31/03/2026
Mr. Paul W. Graves Independent Director 31/03/2026
Ms. Birgit Girshick Chief Operating Officer and Director 09/01/2026
Mr. George Llado, Sr Independent Director 31/03/2026
Ms. Reshema Kemps-Polanco Independent Director 31/03/2026
Mr. Abraham Ceesay Director 31/03/2026
Mr. James C. Foster Chairman of the Board, President and Chief Executive Officer 09/01/2026
Dr. Martin W. Mackay, PhD Independent Director 09/01/2026
Dr. Nancy C. Andrews, M.D.,PhD Independent Director 31/03/2026
Dr. Craig B. Thompson,M.D. Independent Director 31/03/2026
Ms. Virginia M. Wilson Independent Director 31/03/2026
 
所屬ETF (更新日期: 02/05/2026 02:48)
代號 名稱 佔比% 持有日期
MNZLManzil Russell Halal USA Broad MarketETF0.0001%29/04/2026
TOPCiShares S&P 500 3% Capped ETF0.00005%29/04/2026
QRFTQRAFT AI-Enhanced US Large Cap ETF0.00004%29/04/2026
SPXDXtrackers S&P 500 Divers Sect Weight ETF0.00004%29/04/2026
GTPEGoldman Sachs MSCI Wld Priv Eq RtTrkrETF0.00004%29/04/2026
CHRIGlobal X S&P 500 Christian Values ETF0.00001%29/04/2026
BBBCYBER HORNET S&P500 Bitcoin 75/25StgyETF0.00001%29/04/2026
TRUHVaneck Healthcare TruSector ETF0.00001%29/04/2026
EGLEGlobal X S&P 500 U.S. Rev Ldrs ETF0.00001%29/04/2026
XCLRGlobal X S&P 500® Collar 95-110 ETF0.000004%29/04/2026
XTRGlobal X S&P 500® Tail Risk ETF0.000004%29/04/2026
FBProshares S&P 500 Dynamic Buffer ETF0.000002%28/02/2026
AAUSAlpha Architect US Equity ETF<0.000001%05/12/2025
ACEPARS Core Equity ETF<0.000001%11/12/2025
ACIOAptus Collared Investment Opp ETF<0.000001%05/03/2026
ACWIiShares MSCI ACWI ETF<0.000001%04/03/2026
AIEQAmplify AI Powered Equity ETF<0.000001%03/11/2025
ALTLPacer Lunt Large Cap Alternator ETF<0.000001%03/02/2026
AOMiShares Core 40/60 Moderate Allc ETF<0.000001%06/03/2026
AQECAQE Core ETF<0.000001%28/11/2025
  1    2    3    4    5    6    7    8   9    10    11    12  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.